Breakthrough status in cystic fibrosis sends Proteostasis up by half

13 March 2018
2019_biotech_test_vial_discovery_big

The cystic fibrosis (CF) specialist Proteostasis Therapeutics (Nasdaq: PTI) made gains of 47% in Tuesday morning’s trading as it entered the afternoon at $6.13 per share.

Investors were reacting to news that the company has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for PTI-428, its CF transmembrane conductance regulator (CFTR) amplifier.

The status applies for the treatment of CF in homozygous patients for the F508del mutation who are receiving Vertex Pharmaceuticals’ (Nasdaq: VRTX) Orkambi (lumacaftor/ivacaftor) as background therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology